Flt3 Ligand Human

Flt3 Ligand is a small molecule that binds to the Flt3 receptor, a member of the class III receptor tyrosine kinases (RTKs). The binding of FLT3L to its receptor activates the receptor’s tyrosine kinase activity, leading to a cascade of downstream signaling events that promote the survival and proliferation of hematopoietic progenitor cells .

In vivo, FLT3L is known to induce the mobilization of hematopoietic progenitors and stem cells. This mobilization is crucial for the immune system’s ability to respond to infections and other challenges. Additionally, FLT3L plays a role in the development of dendritic cells (DCs), which are essential for linking innate and adaptive immunity by recognizing pathogens and priming pathogen-specific immune responses .

Recombinant human Flt3 Ligand is produced using various expression systems, including E. coli and baculovirus-insect cells. The recombinant protein is typically purified to high levels of purity, often exceeding 95%, and is used in various research and clinical applications .

Recombinant FLT3L is widely used in research to study hematopoiesis and immune responses. It is also being explored for its potential therapeutic applications, particularly in cancer treatment, where it may help enhance the immune system’s ability to target and destroy cancer cells .

Recombinant human Flt3 Ligand is usually provided as a lyophilized powder, which can be reconstituted for use in experiments. It is stable for up to twelve months when stored at -20°C to -80°C under sterile conditions. It is recommended to avoid repeated freeze-thaw cycles to maintain the protein’s activity .